Our Story

Founded in 2015, MGC Pharma aims to provide patients with the highest standard of phytomedicines in order to improve the quality of life for millions across the globe.
Our vision is to have a global impact on undertreated medical conditions and diseases, using the power of plant-based medicine in novel combinations by using technology to harness knowledge and science to achieve our “Nature to Medicine” strategy.

Roby Zomer
Co-Founder & CEO

Our journey so far


Listed on the London Stock Exchange following a £6.5 million fundraise.
Signed a three-year US$24m US Supply and Distribution Agreement with AMC to distribute MGC’s pharmaceutical products across the USA.
CannEpil® was made available for free under the Irish healthcare system to patients with refractory epilepsy for the first time.
Record sales of our proprietary phytocannabinoid products, with sales of over $2m for the first time


Completion of Phase IIb clinical trial of ArtemiC™, showing its effectiveness in the treatment of COVID-19.

Progress on clinical in-vitro research program focused on cannabinoid formulations in the development of treatment for glioblastoma showing cannabinoid preparations can successfully inhibit tumour cell viability and cause a significant percentage of glioblastoma cells to undergo “programmed cell death”.


MGC Pharma received full Good Manufacturing Practice (GMP) Certification and a Manufacturing License at our European medical cannabis compounding and manufacturing facility in Slovenia, enabling our medicinal products to be commercialised for the first time.

Long-term agreement signed to develop GMP production and manufacturing facility in Malta, our first facility in the EU within the medicinal cannabis sector.

Appointment of Roby Zomer as Managing Director of MGC Pharma. Production of our first commercial batch of epilepsy medicine, CannEpil™, which was made available to patients in Australia for the first time, following receipt of Human Research Ethics Committee endorsement from St Vincent Hospital, Melbourne.
Completed successful $10m fundraise to support Pharmaceutical research and clinical trials. Entered into collaboration with the Royal Melbourne Institute of Technology on a suite of medicinal cannabis research initiatives focused on treatment of cancers.
We are just scratching the surface of where plant-based treatments, intersected with modern science, will bring us back to balanced global health

Dr. Jonathan Grunfeld

VP Medical Innovation
Suffering from chronic back pain for over 15 years I have struggled to maintain effective sleep due to constantly tossing and turning to get comfortable. Using MP1:1 25mg/ml CBD 25mg/ml THC not only helps with my pain, but it also relaxes my body and ensures that my sleep patterns are more consistent.


I was diagnosed with Shingles a few years ago and after being in constant pain I was advised to try CBD Oil. After trying a few different products, I decided to try MGC’s CannEpil and I have found that it has helped to reduce the severe headaches I was suffering from and made life so much brighter.



Some of our success stories

We are now making giant strides, taking our pipeline of clinical products to market and pursuing extensive research and development over the past few years. Our successes thus far are beginning to improve patients’ lives around the world.

See how we are helping
improve lives

Screenshot 2021-11-11 111536

Future Roadmap

We specialise in the development and production of phytomedicines and are proud to have qualified and passionate experts on our team.


Research & Development

We pride ourselves on bringing together the most qualified and passionate experts and leaders in the biopharmaceutical industry.


Investor Centre

We value the ongoing support of our Shareholders and pride ourselves on maintaining the best corporate governance practices for the company’s ASX and LSE Investors.

Leading the global shift towards plant-based, naturally harmonious medicines, improving lives and public health.

Rob Clements

Chief Commercial Officer

After starting his career with an initial spell in the City of London Rob joined the pharmaceutical industry in 1991. Over the following decade he progressed rapidly through field roles to Marketing Management. He then established his own consultancy specialising in relationship marketing and product launch for healthcare companies.

He subsequently worked in business development roles identifying potential product acquisitions – both prescription and OTC – the development and launch of medical devices and general strategic functions. His roles included improving business performance and company morale, and oversight of companies’ core marketing of ethical brands.

From 2011 Rob headed a pan-national team for Forest Laboratories delivering new ethical products to markets alongside management of the existing portfolio. As Director both of Marketing and Commercial operations he was also directly responsible for budgeting, planning and data provision, whilst remaining closely involved with the assessment of BD opportunities.

An expert in specialist disease marketing and business development Rob has also worked extensively on a number of proposed private equity asset buyouts in addition to previous consultancy work.

From 2019 he worked with Healthcare at Home (now Sciensus Rare) to help establish an international rare medicines division. As Vice President of Business Development his role included ongoing development and refinement of the service offering and building new business opportunities; from strategic partnerships and potential MA acquisitions through to establishing Sciensus Rare’s global footprint.